Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Sesques

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Plos One|December 4, 2020
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effectsJuliette Périchou, Florence Ranchon, Chloé Herledan, et al.
Blood Advances|July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapyKai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Frontiers in Oncology|November 15, 2024
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapyPierre Sesques, Lionel Karlin, Emmanuel Massy, et al.
Hematological Oncology|July 11, 2024
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospitalCaroline Le Lan, Aurélien Belot, Camille Golfier, et al.
Hematological Oncology|January 19, 2020
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab eraPierre Sesques, Jessie Bourcier, Camille Golfier, et al.
Leukemia & Lymphoma|November 1, 2021
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective studyGuillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, et al.
Biomarker Research|September 13, 2024
18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burdenLing-Shuang Sheng, Rong Shen, Zi-Xun Yan, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Leukemia|April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood Advances|April 19, 2022
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphomaEstelle Bourbon, Pierre Sesques, Morgane Gossez, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Plos One|December 4, 2020
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effectsJuliette Périchou, Florence Ranchon, Chloé Herledan, et al.
Blood Advances|July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapyKai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Frontiers in Oncology|November 15, 2024
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapyPierre Sesques, Lionel Karlin, Emmanuel Massy, et al.
Hematological Oncology|July 11, 2024
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospitalCaroline Le Lan, Aurélien Belot, Camille Golfier, et al.
Hematological Oncology|January 19, 2020
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab eraPierre Sesques, Jessie Bourcier, Camille Golfier, et al.
Leukemia & Lymphoma|November 1, 2021
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective studyGuillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, et al.
Biomarker Research|September 13, 2024
18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burdenLing-Shuang Sheng, Rong Shen, Zi-Xun Yan, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Leukemia|April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood Advances|April 19, 2022
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphomaEstelle Bourbon, Pierre Sesques, Morgane Gossez, et al.
Pageof 7